Vor Ort
Merkzettel Warenkorb
  • Produktbild: Pharmacology of Endogenous Neurotoxins
  • Produktbild: Pharmacology of Endogenous Neurotoxins

Pharmacology of Endogenous Neurotoxins A Handbook

49,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.10.2012

Herausgeber

Andreas Moser

Verlag

Birkhäuser Boston

Seitenzahl

273

Maße (L/B/H)

25,4/17,8/1,7 cm

Gewicht

561 g

Auflage

1998

Sprache

Englisch

ISBN

978-1-4612-7375-2

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.10.2012

Herausgeber

Andreas Moser

Verlag

Birkhäuser Boston

Seitenzahl

273

Maße (L/B/H)

25,4/17,8/1,7 cm

Gewicht

561 g

Auflage

1998

Sprache

Englisch

ISBN

978-1-4612-7375-2

Herstelleradresse

Springer Nature c/o IBS
Benzstrasse 21
48619 Heek
DE

Email: Tanja.Keller@springer.com

Kundinnen und Kunden meinen

0 Bewertungen

Informationen zu Bewertungen

Zur Abgabe einer Bewertung ist eine Anmeldung im Konto notwendig. Die Authentizität der Bewertungen wird von uns nicht überprüft. Wir behalten uns vor, Bewertungstexte, die unseren Richtlinien widersprechen, entsprechend zu kürzen oder zu löschen.

Die Bewertungen sind nach Format, Anzahl Sterne und Datum sortiert.

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kund*innen durch Ihre Meinung

Kundinnen und Kunden meinen

0 Bewertungen filtern
  • Produktbild: Pharmacology of Endogenous Neurotoxins
  • Produktbild: Pharmacology of Endogenous Neurotoxins
  • A Neurotoxins.- 1 Isoquinoline Derivatives.- 1. Introduction.- 2. Tetrahydroisoquinoline (TIQ).- 2.1 Presence of TIQ in nature and in food.- 2.2 Methods for identification and measurement of TIQ.- 2.3 Presence of TIQ in tissues.- 2.4 Endogenous synthesis of TIQ.- 2.5 Parkinsonism caused by TIQ.- 2.6 Metabolism of TIQ in the brain.- 3. 1,2-Dihydroisoquinoline.- 4. 4-Hydroxy-TIQ.- 5. 1-Benzyl-TIQ.- 6. 1-Phenyl-N-methyl-TIQ and 1-phenyl-TIQ.- 7. Salsolinol (SAL).- 7.1 Presence of SAL in tissues, body fluids, food, and nature.- 7.2 Biosynthetic pathway of SAL.- 7.3 Neurotoxicity of SAL.- 7.4 Metabolism of SAL.- 8. Norsalsolinol.- 9. N-Methyl-salsolinol and N-methyl-norsalsolinol.- 10. 1,2,3,4-Tetrahydro-2-methyl-4,6,7-i soquinolinetriol.- 11. Methods for identification and measurement of catecholic TIQs.- 12. The sites of toxicological activity.- 12.1 Inhibition of mitochondrial respiratory enzymes.- 12.2 Hydroxyl radical formation.- 2 TIQ Derivatives in the Human Central Nervous System.- 1. History of the Presence of TIQ derivatives.- 2. Analytical Methods.- 2.1 Cerebrospinal Fluid (CSF).- 2.1.1 Lumbar Puncture.- 2.1.2 High Performance Liquid Chromatography.- 2.2 Urine.- 2.2.1 Urine measurements of Salsolinol.- 2.2.2 Affinity chromatography.- 2.2.3 High Performance Liquid Chromatography.- 3. Frequency and TIQ Levels measured by HPLC-ECD.- 3.1 N-Methyl-norsalsolinol.- 3.2 Salsolinol.- 4. TIQ Derivatives and Dopamine Metabolites.- 5. Stereospecifity and Enantiomeric Separation.- 6. Cerebral Lesions by TIQ Derivatives.- 6.1 TIQ, 1-Methyl-TIQ, 2-Methyl-TIQ.- 6.2 N-Methyl-[R]-salsolinol.- 6.3 N-Methyl-norsalsolinol.- 6.4 N-Methyl-4-hydroxy-norsalsolinol.- 7. Hallucinosis and TIQ Derivatives.- 3 Animal Model of Parkinson’s Disease Prepared by N-Methyl-R-Salsolinol.- 1. MPTP and N-Methylation.- 2. Preparation of a rat model of Parkinson’s disease.- 2.1 Materials.- 2.2 Animal experiments.- 3. Behavior observation.- 3.1 Behavior changes due to perturbation in dopaminergic system.- 4. Biochemical analysis in the brain.- 4.1 Methods.- 4.2 Quantitative analyses of monoamines, their metabolites and isoquinolines.- 4.3 Enantiomeric analysis of salsolinol derivatives.- 4.4 Assay of tyrosine hydroxylase activity.- 4.5 Biochemical changes by infusion of N-methyl-[R]-salsolinol and DMDHIQ+.- 4.6 Changes of monoamines and their metabolites.- 4.7 Accumulation of N-methyl-[R]-salsolinol and DMDHIQ+.- 4.8 Reduction of tyrosine hydroxylase activity.- 5. Histological study.- 5.1 Methods for histological analysis.- 5.2 Cytotoxicity in the striatum.- 5.3 Depletion of dopamine neurons in the substantia nigra.- 6. Discussion.- 4 Putative Endogenous Neurotoxins Derived from the Biogenic Amine Neurotransmitters.- 1. Introduction.- 2. Alzheimer’s disease.- 3. Ischemia-Reperfusion.- 4. Methamphetamine.- 5. In vitro oxidation chemistry of the biogenic amine neurotransmitter.- 5.1 In vitro oxidation chemistry of 5-hydroxytryptamine.- 5.2 In vitro oxidation chemistry of dopamine.- 5.3 In vitro oxidation chemistry of norepinephrine.- 6. In vivo oxidation chemistry of the biogenic amine neurotransmitter.- 6.1 In vivo oxidation of 5-hydroxytryptamine.- 6.2 In vivo oxidation of dopamine and norepinephrine.- 7. Properties of putative aberrant oxidative metabolites of the biogenic amine neurotransmitters.- 7.1 Redox properties of putative aberrant oxidative metabolites of 5-HT and 5-HTPP.- 7.2 Redox properties of putative aberrant oxidative metabolites of DA and NE.- 8. Neurochemical and neurobiological properties of putative aberrant oxidative metabolites of 5-HT, DA and NE.- 9. Serotonin binding proteins.- 10. Discussion.- 11. Summary.- 5 ?-Carboline Derivatives as Neurotoxins.- 1. Biosynthetic and organic synthetic routes to TH?C’s and ?C’s.- 2. Overview of the effects of ?C’s and their metabolic derivatives on the nervous system.- 3. Measurement and analysis of TH?C’s, ?C’s and their derivatives.- 4. Enzymatic formation of N-methylated ?C cations from nonpolar ?C’s.- 5. Uptake and intracellular actions of N-methylated ?C cations.- 6. Neurotoxicity in vitro of N-methylated ?C cations.- 7. Neurotoxicity in vivo of N-methylated ?C cations.- 8. Endogenous presence of TH?C’s, ?C’s and their N-methylated derivatives in animals and humans.- 6 Highly Halogenated Tetrahydro-?-Carbolines as a New Class of Dopaminergic Neurons.- 1. Introduction.- 2. Chloral-derived THBCs as potential mammalian alkaloids with expected neurotoxic properties.- 2.1 Synthetic route for the preparation of TaClo.- 2.2 TaClo as a chiral compound: elucidation of the absolute configuration.- 2.3 Ability of TaClo to cross the blood-brain barrier.- 2.4 De novo formation of TaClo in rats treated with its putative precursors.- 3. Lesion studies.- 3.1 Effects of TaClo in cell culture on cell integrity and dopamine metabolism.- 3.2 Inhibition of the mitochondrial respiration.- 3.3 Behavioral studies on rats after intraperitoneal application of TaClo.- 3.4 Striatal dopamine metabolism in the rat after intranigral injection of TaClo.- 4. Outlook.- 7 pros -Methylimidazoleacetic Acid: A Potential Neurotoxin in Brain?.- 1. Introduction.- 2. Biochemical origin of p-MIAA.- 3. Presence of p-MIAA in nature.- 4. Methods of measurement of p-MIAA.- 5. Localization of p-MIAA in brain.- 6. p-MIAA in CSF of patients with Parkinson’s disease.- 7. p-MIAA and studies with mice given MPTP.- 8. p-MIAA and release of the excitoneurotoxin, glutamate.- 9. p-MIAA measured in CSF of patients with chronic schizophrenia.- 10. p-MIAA in brain and lack of changes with drugs.- 11. Summary and conclusions.- B Metabolism.- 8 Bioactivation of Azaheterocyclic Amines Via S-adenosyl-L-methionine-dependent N-methyltransferases..- 1. Methyltransferase.- 1.1 Nicotinamide N-methyltransferase.- 1.2 Histamine N-methyltransferase.- 1.3 Phenylethylamine N-methyltransferase.- 1.4 Amine N-methyltransferase.- 1.5 Others.- 2. Assay procedures.- 3. Methyl donor, SAM.- 4. Substrate for N-methyltransferase, neurotoxin precursor.- 4.1 MPTP analogues.- 4.2 ?-Carbolines and their tetrahydro forms.- 4.3 TIQ and 6,7-DHTIQ.- 4.4 1-Aromatic substitution of TIQs.- 5. Possible formation of azaheterocyclics via SAM-dependent N-methylation.- 9 Tyrosine Hydroxylase: Biochemical Properties and Short-term Regulation In Vitro and In Vivo.- 1. Basic properties of tyrosine hydroxylase.- 2. Structure and function.- 3. Assays for tyrosine hydroxylase.- 4. Regulation of tyrosine hydroxylase.- 4.1 Feedback inhibition.- 4.2 Enzyme phosphorylation and activation in vitro.- 4.3 Regulation of tyrosine hydroxylase by protein phosphorylation and by dopamine autoreceptor in dopaminergic nerve terminals.- 10 Tyrosine Hydroxylase and Endogenous Neurotoxins.- 1. Tyrosine hydroxylase.- 1.1 Genetic aspects: Transcription and translation.- 1.2 Molecular structure.- 1.3 Investigation of tyrosine hydroxylase expression.- 1.4 An assay of tyrosine hydroxylase enzyme activity.- 2. The effect of neurotoxins on tyrosine hydroxylase.- 2.1 Models of neurotoxicity involving tyrosine hydroxylase.- 2.2 Quinoline and isoquinoline derivatives.- 2.3 ?-Carbolines.- 3. Summary.- 11 Monoamine Oxidase: Interaction with Isoquinoline Derivatives.- 1. Monoamine oxidase.- 1.1 Introduction.- 1.2 Classification.- 1.3 Genetic differences.- 1.4 Occurrence.- 1.5 Reaction mechanism.- 1.6 Ravin cofactor.- 2. Interaction between MAO and isoquinoline derivatives.- 2.1 MPTP-model.- 2.2 MPTP-like substances.- 2.3 Isoquinoline derivatives.- 2.4 Isoquinoline derivatives as MAO inhibitor.- 2.5 Inhibition pattern of N-methyl-norsalsolinol.- 2.6 Chemical structure and inhibitory activity.- 12 Toxicity and Pharmacological Effects of Salsolinol in Different Cultivated Cells.- 1. Blood-brain barrier.- 2. Technical procedures.- 2.1 Materials.- 2.2 Cell culture.- 2.3 Cytotoxicity.- 2.4 Electron microscopy.- 2.5 Effect of salsolinol on the ?-endorphin release of AtT-20 cells.- 2.6 Effect of salsolinol on the POMC gene expression.- 2.7 Receptor binding analysis.- 2. Cytotoxicity of salsolinol.- 3. Binding studies with salsolinol on dopamine receptor subtypes.- 4. Effect of salsolinol on POMC gene expression and ?-endorphin release of AtT-20 cells.